KAWASAKI, Japan--(BUSINESS WIRE)--PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today that it has entered into a broad-based multi-target discovery and development agreement with Osaka-based Santen Pharmaceuticals Co., Ltd., (“Santen”). Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify macrocyclic/constrained peptides against multiple ophthalmic disease targets of interest selected by Santen, and to optimize hit peptides into therapeutic peptides products for such indications. PeptiDream will be responsible for drug discovery and part of preclinical development aspects, while Santen will be responsible for preclinical and clinical development of identified candidates. Santen is a specialized pharmaceutical company with a singular focus on ophthalmology, a disease area to which PeptiDream’s constrained peptides have the potential to become ideal therapeutics.
Under the terms of the agreement, PeptiDream would receive an undisclosed upfront payment and research funding and is eligible to receive preclinical, clinical, and commercialization milestone payments from Santen. In addition, PeptiDream is eligible to receive royalties on sales of any products that arise from the collaboration.
[Comment from Keiichi Masuya, EVP of PeptiDream]
“We are
extremely excited to be joining forces with Santen, a leader in the area
of ophthalmic disease treatments. Within the very broad
therapeutic potential of our constrained peptides, we believe our
constrained peptides are ideally suited for the treatment of eye
disease, and this deal represents one of our broadest discovery and
development agreements to date, with PeptiDream responsible for all
early drug discovery and preclinical development, before passing
candidates to Santen for preclinical development and clinical trials.”
In the past eight years, PeptiDream has established funded discovery collaborations with 18 of the leading pharmaceutical companies; Amgen, AstraZeneca, Bristol-Myers-Squibb, Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, Merck & Co., Inc., Kenilworth, NJ, USA, Sanofi, Teijin, Kyorin, Ipsen, Genentech, Shionogi, Asahi Kasei, Janssen, and Bayer all of which are active and ongoing. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb, Novartis, Lilly, Genentech, Shionogi, and Merck (Merck & Co. Inc., Kenilworth NJ, USA).
